Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 3 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
BIOND BIOLOGICS LTD. is currently engaged in the patent prosecution process within the Biotechnology & Pharmaceuticals technology area. The portfolio contains 4 pending office actions, reflecting a steady level of activity in this complex and highly regulated field. This workload is distributed across 4 distinct examiners, which suggests that the company's research and development efforts cover a variety of biological or pharmaceutical innovations.
The prosecution is organized within 3 distinct art units. This level of concentration indicates that while the examiners are diverse, the technical subject matter remains focused within a few specific regulatory categories. For practitioners, this distribution requires a strategy that accounts for the unique examination standards and precedents prevalent in these 3 art units.
DUFFY, BRADLEY is the busiest examiner for this portfolio, currently handling 1 pending office action. Although the pending matters are spread across multiple individuals, the specific approach of this examiner will be a key factor in the outcome of the assigned application. Navigating the Biotechnology & Pharmaceuticals landscape effectively involves balancing these individual examiner interactions with the broader requirements of the assigned art units.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (25%) |
| Double-patenting + other | 1 (25%) |
| Multi-statute (no §101) | 2 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DUFFY, BRADLEY | 1 | 54.4% | +46.0% |
| DRISCOLL, MAUREEN VARINA | 1 | 64.9% | +41.8% |
| GEORGE, DENNIS CHERIAN | 1 | 42.9% | +72.7% |
| POHNERT, STEVEN C | 1 | 12.5% | +18.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18689483 | CD28 SHEDDING BLOCKING AGENTS | DUFFY, BRADLEY | — |
| 17915761 | IMMUNOMODULATORY COMPOSTIONS AND USE THEREOF | GEORGE, DENNIS CHERIAN | — |
| 17781966 | SOLUBLE CD28 LEVELS DURING IMMUNOTHERAPY | POHNERT, STEVEN C | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18124717 | SOLUBLE CD28 LEVELS AFTER IMMUNOTHERAPY | DRISCOLL, MAUREEN VARINA | 8d |
| 18689483 | CD28 SHEDDING BLOCKING AGENTS | DUFFY, BRADLEY | — |
| 17915761 | IMMUNOMODULATORY COMPOSTIONS AND USE THEREOF | GEORGE, DENNIS CHERIAN | — |
| 17781966 | SOLUBLE CD28 LEVELS DURING IMMUNOTHERAPY | POHNERT, STEVEN C | — |
| Art Unit | Apps |
|---|---|
| 1644 | 2 |
| 1643 | 1 |
| 1683 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18689483 | CD28 SHEDDING BLOCKING AGENTS | DUFFY, BRADLEY | 1643 | §102§112 | Non-Final OA | — | Pending | Mar 06, 2024 |
| 18124717 | SOLUBLE CD28 LEVELS AFTER IMMUNOTHERAPY | DRISCOLL, MAUREEN VARINA | 1644 | §112DP | Non-Final OA | 8d | Pending | Mar 22, 2023 |
| 17915761 | IMMUNOMODULATORY COMPOSTIONS AND USE THEREOF | GEORGE, DENNIS CHERIAN | 1644 | §103§112 | Non-Final OA | — | Pending | Sep 29, 2022 |
| 17781966 | SOLUBLE CD28 LEVELS DURING IMMUNOTHERAPY | POHNERT, STEVEN C | 1683 | §101§112 | Final Rejection | — | Pending | Jun 02, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialBIOND BIOLOGICS LTD. has 4 pending office actions as of October 2026, spread across 3 art units and 4 examiners.
Bradley Duffy has the most, with 1 of BIOND BIOLOGICS LTD.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
